MHRA authorises Onswik treatment for adults with type 2 diabetes

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised Onswik, known as insulin efsitora alfa, on 13 October 2026 for treating adults with type 2 diabetes. This long-acting basal insulin allows for once-weekly injections, potentially reducing the burden of care for patients from 365 injections per year to just 52. The medication works by promoting glucose uptake in cells and limiting liver glucose production, helping to manage blood sugar levels effectively.

For residents in the UK living with type 2 diabetes, this development represents a significant shift in daily management. Clinical trial results indicated that this weekly treatment offers glycaemic control comparable to traditional once-daily basal insulins. Following the MHRA licensing, the National Institute for Health and Care Excellence (NICE) has confirmed its support for insulin efsitora alfa as a recommended treatment option for eligible adult patients, marking a positive step for diabetes care accessibility.

While the medication offers convenience, the most frequently reported side effect is hypoglycaemia, or low blood sugar. The MHRA continues to monitor the safety of this drug through its standard surveillance systems. Patients are advised to consult their healthcare providers, including nurses or pharmacists, if they encounter any side effects. Furthermore, it is encouraged that individuals report any concerns through the Yellow Card scheme via the website or the mobile app. Those currently undergoing treatment should speak with their GP regarding whether this new option is suitable for their specific health needs.

This summary was prepared with AI assistance. Please verify accuracy via the source.

Source: Olay Gazete